The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.

Abstract excerpt

BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung adenocarcinoma (LUAD) typically demonstrates limited response to neoadjuvant immunotherapy (NIT). Elucidating the immune determinants that differentiate responders from non-responders was critical for optimizing immunotherapy strategies. This study aimed to characterize the tumour microenvironment features of KRAS-mutant LUAD following...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Aged